Company Overview and News

25
Your Daily Pharma Scoop: Audentes's New Designation, Esmya Rejected, Agilent Approved

2018-08-23 seekingalpha - 1
Discussions: Audentes Therapeutics' (BOLD) AT132 receives FDA designation of a Regenerative Medicine Advanced Therapy (‘RMAT). The therapy is indicated for treatment of X-linked myotubular myopathy (‘XLMTM). RMAT is in many ways similar to the Breakthrough Therapy status and allows accelerated review of a drug along with more frequent interaction with the FDA during the development stage. The therapy has already acquired Rare Pediatric disease, Fast track and Orphan Drug Designation in the U.
IRWD ALPMF AZN NURO GSK CANF BOLD GBHPF 4503 MYL ALPMY AGN MRK GHG GSK DCTH TNXP DCTHD BMY ALNY

3
Global Hemp Group Provides Update on Successful Launch of Cash Crop Today Investor & Business Resource Summit

2018-06-14 globenewswire
VANCOUVER, British Columbia, June 14, 2018 (GLOBE NEWSWIRE) -- via NetworkWire - GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) is pleased to announce that the Company’s 50% owned subsidiary Cash Crop Today Media, LLC hosted its first Investor and Business Resource Summit this past weekend in Beverly Hills, California.
GBHPF GHG

5
Marijuana Company of America and Global Hemp Group Provide Update on New Brunswick Hemp Project

2018-05-22 globenewswire
ESCONDIDO, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC:MCOA), an innovative hemp and cannabis corporation, is pleased to provide an update on its New Brunswick Hemp Project with joint venture partner, Global Hemp Group Inc. (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) (the “Partners”).
GBHPF GHG MCOA

5
Global Hemp Group and Marijuana Company of America Provide an Update on Operations for Their Joint Venture CBD Hemp Farm in Scio, Oregon

2018-05-15 globenewswire
VANCOUVER, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) and joint venture partner Marijuana Company of America, Inc. (OTC:MCOA) (the “Partners”) are pleased to provide an update on their CBD hemp farming project in Scio, Oregon (the “Project”).
GBHPF GHG MCOA

5
Global Hemp Group and Marijuana Company of America Form Joint Venture to Cultivate High Yielding CBD Hemp in Scio, Oregon

2018-05-09 globenewswire
VANCOUVER, B.C., May 09, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) is pleased to announce that is has signed a Joint Venture Agreement (the “Agreement”) with MARIJUANA COMPANY OF AMERICA, INC. (OTC:MCOA) to cultivate high yielding CBD hemp at its recently acquired 109 acre farm (see news release of May 1, 2018) in Scio, Oregon (the “Project”).
GBHPF GHG MCOA

5
Marijuana Company of America and Global Hemp Group Form Joint Venture to Cultivate High Yielding CBD Hemp in Scio, Oregon

2018-05-09 globenewswire
ESCONDIDO, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – MARIJUANA COMPANY OF AMERICA, INC. (“MCOA” or the “Company”) (OTC:MCOA), an innovative hemp and cannabis corporation, is pleased to announce that it has signed a Joint Venture Agreement (the “Agreement”) with GLOBAL HEMP GROUP INC. (“GHG”) (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) to cultivate legal high yielding CBD from industrial hemp at its recently acquired 109 acre farm (see news release of May 1, 2018) in Scio, Oregon.
GBHPF GHG MCOA

5
Marijuana Company of America and Global Hemp Group Announce Acquisition of 109 Acres of Prime Agricultural Property for Hemp CBD Production in Oregon

2018-05-01 globenewswire
ESCONDIDO, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – MARIJUANA COMPANY OF AMERICA, INC. (“MCOA” or the “Company”) (OTC:MCOA) is pleased to announce that the Company, in partnership with Global Hemp Group Inc. (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) has acquired a 109-acre agricultural property in Scio, Oregon (the “Property”) for the cultivation of high CBD yielding hemp for the upcoming 2018 growing season.
GBHPF GHG MCOA

5
Global Hemp Group and Marijuana Company of America Announce Acquisition of 109 Acres of Prime Agricultural Property for Hemp CBD Production in the State of Oregon

2018-05-01 globenewswire
VANCOUVER, British Columbia, May 01, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE:GHG) (OTC:GBHPF) (FRANKFURT:GHG) is pleased to announce that the Company, in partnership with Marijuana Company of America, Inc. (OTC:MCOA) has acquired a 109 acre agricultural property in Scio, Oregon (the “Property”) for the cultivation of high CBD yielding hemp for the upcoming 2018 growing season.
GBHPF GHG MCOA

6
Cannabis Science, Inc. Announces Support for the Global Hemp Group and Senator Mitch Mcconnell's Hemp Legislation; CBIS Ceo Eyes 4/20 for a CBIS Pharmacy Grand Opening Party

2018-03-27 globenewswire
IRVINE, CA , March 27, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it fully supports the Global Hemp Group and the Hemp Farming Act of 2018.
GBHPF CBIS GHG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CNSX:GHG / Global Hemp Group Inc on message board site Silicon Investor.

DGHG DGHG DGHG